EpCAM aptamer-siRNA chimera targets and regress epithelial cancer

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Subramanian, Nithya ^a,b   Kanwar, Jagat R ^b   Kanwar, Rupinder K ^b   Sreemanthula, Jagadeeshbabu ^a   Biswas, Jyotirmay ^a   Khetan, Vikas ^c   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b DEAKIN UNIVERSITY   (Australia)

^c MEDICAL RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; SMALL INTERFERING RNA; STATHMIN; SURVIVIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; CELL ADHESION MOLECULE; RIBONUCLEASE III; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL CANCER CELL LINE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CANCER STEM CELL; CHEMISTRY; DRUG SCREENING; ENDOCYTOSIS; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KINETICS; MCF-7 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN MICROARRAY; PROTEIN TERTIARY STRUCTURE; RETINOBLASTOMA; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOCYTOSIS; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KINETICS; MCF-7 CELLS; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASTIC STEM CELLS; PROTEIN ARRAY ANALYSIS; PROTEIN STRUCTURE, TERTIARY; RETINOBLASTOMA; RIBONUCLEASE III; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941337167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132407     Document Type: Article

References (50)

1. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer research. 2009; 69(14):5627-9. doi: 10.1158/0008-5472.CAN-09-0654 PMID: 19584271.
2. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. British journal of cancer. 2007; 96 (3):417-23. doi: 10.1038/sj.bjc.6603494 PMID: 17211480; PubMed Central PMCID: PMC2360029.
3. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010; 31(11):1913-21. doi: 10.1093/carcin/bgq187 PMID: 20837599.
4. Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, et al. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. Journal of cancer research and clinical oncology. 2009; 135(9):1277-85. doi: 10.1007/s00432-009-0569-5 PMID: 19294417.
5. Mitra M, Kandalam M, Verma RS, UmaMaheswari K, Krishnakumar S. Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Molecular vision. 2010; 16:828-42. PMID: 20461151; PubMed Central PMCID: PMC2866575.
6. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer research. 2004; 64 (16):5818-24. doi: 10.1158/0008-5472.CAN-04-0754 PMID: 15313925.
7. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nature cell biology. 2009; 11(2):162-71. doi: 10.1038/ncb1824 PMID: 19136966.
8. Schnell U, Kuipers J, Giepmans BN. EpCAM proteolysis: new fragments with distinct functions? Bioscience reports. 2013; 33(2):e00030. doi: 10.1042/BSR20120128 PMID: 23409978; PubMed Central PMCID: PMC3601740.
9. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF, et al. Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. The Journal of biological chemistry. 2010; 285(12):8719-32. doi: 10.1074/jbc.M109.077081 PMID: 20064925; PubMed Central PMCID: PMC2838295.
10. Ogura E, Senzaki H, Yoshizawa K, Hioki K, Tsubura A. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer research. 1998; 18(5B):3669-75. PMID: 9854475.
11. Salomon J, Goulet O, Canioni D, Brousse N, Lemale J, Tounian P, et al. Genetic characterization of congenital tufting enteropathy: epcam associated phenotype and involvement of SPINT2 in the syndromic form. Human genetics. 2014; 133(3):299-310. doi: 10.1007/s00439-013-1380-6 PMID: 24142340.
12. Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21(2):275-82. doi: 10.1093/annonc/mdp314 PMID: 19633042.
13. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer science. 2011; 102(5):991-8. doi: 10.1111/j.1349-7006. 2011.01897.x PMID: 21281402.
14. Song KM, Lee S, Ban C. Aptamers and their biological applications. Sensors. 2012; 12(1):612-31. doi: 10.3390/s120100612 PMID: 22368488; PubMed Central PMCID: PMC3279232.
15. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346(6287):818-22. doi: 10.1038/346818a0 PMID: 1697402.
16. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249(4968):505-10. PMID: 2200121.
17. Song Y, Zhu Z, An Y, Zhang W, Zhang H, Liu D, et al. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Analytical chemistry. 2013; 85(8):4141-9. doi: 10.1021/ac400366b PMID: 23480100.
18. Davidson BL. All in the RNA family. Nature biotechnology. 2006; 24(8):951-2. doi: 10.1038/nbt0806-951 PMID: 16900139.
19. Subramanian N, Raghunathan V, Kanwar JR, Kanwar RK, Elchuri SV, Khetan V, et al. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Molecular vision. 2012; 18:2783-95. PMID: 23213278; PubMed Central PMCID: PMC3513190.
20. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature biotechnology. 2009; 27(9):839-49. doi: 10.1038/nbt.1560 PMID: 19701187; PubMed Central PMCID: PMC2791695.
21. Bellaousov S, Reuter JS, Seetin MG, Mathews DH. RNAstructure: Web servers for RNA secondary structure prediction and analysis. Nucleic acids research. 2013; 41(Web Server issue):W471-4. doi: 10.1093/nar/gkt290 PMID: 23620284; PubMed Central PMCID: PMC3692136.
22. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic acids research. 2003; 31(13):3406-15. PMID: 12824337; PubMed Central PMCID: PMC169194.
23. Vermeulen A, Behlen L, Reynolds A, Wolfson A, Marshall WS, Karpilow J, et al. The contributions of dsRNA structure to Dicer specificity and efficiency. Rna. 2005; 11(5):674-82. doi: 10.1261/rna.7272305 PMID: 15811921; PubMed Central PMCID: PMC1370754.
24. Subramanian N, Kanwar JR, Athalya P, Janakiraman N, Khetan V, Kanwar RK, et al. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. Journal of biomedical science. 2015; 22(1):4. doi: 10.1186/s12929-014-0108-9 PMID: 25576037.
25. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nature reviews Cancer. 2009; 9(2):143; author reply doi: 10.1038/nrc2499-c1 PMID: 19132011.
26. Gonzalez B, Denzel S, Mack B, Conrad M, Gires O. EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem cells. 2009; 27(8):1782-91. doi: 10.1002/stem.97 PMID: 19544432.
27. Mitra M, Kandalam M, Harilal A, Verma RS, Krishnan UM, Swaminathan S, et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Molecular vision. 2012; 18:290-308. PMID: 22328825; PubMed Central PMCID: PMC3275636.
28. Krishnakumar S, Mohan A, Mallikarjuna K, Venkatesan N, Biswas J, Shanmugam MP, et al. EpCAM expression in retinoblastoma: a novel molecular target for therapy. Investigative ophthalmology & visual science. 2004; 45(12):4247-50. doi: 10.1167/iovs.04-0591 PMID: 15557427.
29. Bruno JG. A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals. 2013; 6(3):340-57. doi: 10.3390/ph6030340 PMID: 24276022; PubMed Central PMCID: PMC3816688.
30. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014; 35 (12):3840-50. doi: 10.1016/j.biomaterials.2014.01.019 PMID: 24486214.
31. Kanwar JR, Shankaranarayanan JS, Gurudevan S, Kanwar RK. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug discovery today. 2014; 19 (9):1309-21. doi: 10.1016/j.drudis.2014.02.009 PMID: 24598791.
32. Germer K, Leonard M, Zhang X. RNA aptamers and their therapeutic and diagnostic applications. International journal of biochemistry and molecular biology. 2013; 4(1):27-40. PMID: 23638319; PubMed Central PMCID: PMC3627066.
33. Marton S, Reyes-Darias JA, Sanchez-Luque FJ, Romero-Lopez C, Berzal-Herranz A. In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules. Molecules. 2010; 15(7):4610-38. doi: 10.3390/molecules15074610 PMID: 20657381.
34. Kwiatt ME, Patel MS, Ross SE, Lachant MT, MacNew HG, Ochsner MG, et al. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study. The journal of trauma and acute care surgery. 2012; 73 (3):625-8. doi: 10.1097/TA.0b013e318265cab9 PMID: 22929493.
35. Liu HY, Gao X. A universal protein tag for delivery of SiRNA-aptamer chimeras. Scientific reports. 2013; 3:3129. doi: 10.1038/srep03129 PMID: 24196104; PubMed Central PMCID: PMC3819613.
36. Bagalkot V, Gao X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS nano. 2011; 5(10):8131-9. doi: 10.1021/nn202772p PMID: 21936502; PubMed Central PMCID: PMC3210423.
37. Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer letters. 2013; 330(1):84-95. doi: 10.1016/j.canlet.2012.11.032 PMID: 23196060.
38. Somasunderam A, Thiviyanathan V, Tanaka T, Li X, Neerathilingam M, Lokesh GL, et al. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry. 2010; 49(42):9106-12. doi: 10.1021/bi1009503 PMID: 20843027; PubMed Central PMCID: PMC2981344.
39. Simon M, Stefan N, Pluckthun A, Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert opinion on drug delivery. 2013; 10(4):451-68. doi: 10.1517/ 17425247.2013.759938 PMID: 23316711.
40. Subramanian N, Sreemanthula JB, Balaji B, Kanwar JR, Biswas J, Krishnakumar S. A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells. Chemical communications. 2014; 50(80):11810-3. doi: 10.1039/c4cc02996h PMID: 25005751.
41. Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Critical reviews in biochemistry and molecular biology. 2011; 46(6):459-77. doi: 10.3109/10409238.2011.614592 PMID: 21955150; PubMed Central PMCID: PMC3233271.
42. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence. 2010; 1(1):4. doi: 10.1186/ 1758-907X-1-4 PMID: 20226078; PubMed Central PMCID: PMC2835998.
43. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Molecular cancer. 2012; 11:73. doi: 10.1186/1476-4598-11-73 PMID: 23009336; PubMed Central PMCID: PMC3497614.
44. Angele S, Treilleux I, Taniere P, Martel-Planche G, Vuillaume M, Bailly C, et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(9):3536-44. PMID: 10999741.
45. Kandalam MM, Beta M, Maheswari UK, Swaminathan S, Krishnakumar S. Oncogenic microRNA 17-92 cluster is regulated by epithelial cell adhesion molecule and could be a potential therapeutic target in retinoblastoma. Molecular vision. 2012; 18:2279-87. PMID: 22969266; PubMed Central PMCID: PMC3436882.
46. Song L, Lin C, Wu Z, Gong H, Zeng Y, Wu J, et al. miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PloS one. 2011; 6(9):e25454. doi: 10. 1371/journal.pone.0025454 PMID: 21980462; PubMed Central PMCID: PMC3181320.
47. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature reviews Cancer. 2004; 4 (1):11-22. doi: 10.1038/nrc1252 PMID: 14708024.
48. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Annals of clinical and laboratory science. 2006; 36(1):23-30. PMID: 16501233.
49. Semple JI, Smits VA, Fernaud JR, Mamely I, Freire R. Cleavage and degradation of Claspin during apoptosis by caspases and the proteasome. Cell death and differentiation. 2007; 14(8):1433-42. doi: 10.1038/sj.cdd.4402134 PMID: 17431426.
50. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical cancer research: CR. 2011; 30:87. doi: 10.1186/1756-9966-30-87 PMID: 21943236; PubMed Central PMCID: PMC3197541.